Combined Pharmacologic Therapy in Postmenopausal Osteoporosis
Yang Shen1, Dona L Gray2, Dorothy S Martinez3
1Endocrinology Clinic, Huntington Health Physicians, 10 Congress Street, Suite 408, Pasadena, CA 91105, USA.
Endocrinology and Metabolism Clinics of North America
|January 30, 2017
Summary
Combining teriparatide with antiresorptive agents for osteoporosis shows mixed results. Small bone density increases were noted with estrogen/SERM and denosumab, but larger trials are needed.
Area of Science:
- Endocrinology
- Pharmacology
- Bone Biology
Background:
- Postmenopausal osteoporosis treatment involves antiresorptive agents like SERMs, bisphosphonates, and denosumab.
- Teriparatide is the sole FDA-approved anabolic agent for osteoporosis.
- Combination therapies of teriparatide with antiresorptives are being investigated for synergistic effects.
Purpose of the Study:
- To review trial designs and outcomes of combining teriparatide with antiresorptive agents.
- To evaluate the efficacy of combination therapies in managing postmenopausal osteoporosis.
Main Methods:
- Review of clinical trials examining combination therapies for osteoporosis.
- Analysis of reported bone density and fracture outcomes.
Main Results:
- Combination therapy of teriparatide and bisphosphonates yielded mixed results.
- Small increases in bone density were observed with teriparatide combined with estrogen/SERM.
- Teriparatide combined with denosumab also showed minor bone density improvements.
Conclusions:
- Clinical studies on teriparatide combination therapies are limited by small sample sizes.
- Lack of fracture outcome data hinders definitive conclusions on efficacy.
- Further large-scale studies are required to establish the benefits of these combination treatments.
Related Concept Videos
01:27Coronary Artery Disease V: Interprofessional Care
357
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
357
01:40Bone Remodeling
40.8K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
40.8K
01:15Drug Dosing: Geriatric Patients
335
Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
335
01:26Angina IV: Management
370
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
370
01:26Atherosclerosis III: Management
540
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
540
01:27Pharmacodynamics in Geriatric Patients: Effects of Age
295
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
295